Cisplatin Plus Gemcitabine for Treatment of Breast Cancer Patients with Brain Metastases: a Preferential Option for Triple Negative Patients?

Erten, Cigdem; Demir, Lutfiye; Somali, Isil; Alacacioglu, Ahmet; Kucukzeybek, Yuksel; Akyol, Murat; Can, Alper; Dirican, Ahmet; Bayoglu, Vedat; Tarhan, Mustafa Oktay

추천

검색

자료유형: 학술저널

저자정보: Erten, Cigdem (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) Demir, Lutfiye (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) Somali, Isil (Department of Medical Oncology, Institute of Oncology, Faculty of Medicine, Dokuz Eylul University) Alacacioglu, Ahmet (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) Kucukzeybek, Yuksel (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) Akyol, Murat (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) Can, Alper (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) Dirican, Ahmet (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) Bayoglu, Vedat (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) Tarhan, Mustafa Oktay (Department of Medical Oncology, Ataturk Training and Research Hospi)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제14권 제6호

발행연도: 2013.1

수록면: 3,711 - 3,717 (7page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: To assess the efficacy and tolerability of Cisplatin plus Gemcitabine combination in patients with brain metastases (BM) from breast cancer (BC). Materials and Methods: Eighteen BC patients with BM who were treated with Cisplatin plus Gemcitabine regimen between 2003-2011 were evaluated. Results: A median of 6 cycles of this regimen were received, in fifteen patients (83.3%) as first-line chemotherapy, in 2 as second-line and in 1 as third-line after diagnosis of BM. Dose reduction was performed in 11 (61.1%) patients; major reasons were neutropenia and leukopenia. Grade III neutropenia and Grade II trombocytopenia rates were 33.3% and 16.7% respectively. Overall response rate (ORR; complete+partial response rate) was 33.4% (n=6) for the entire study population; triple negative patients achieved an 66.6% ORR while hormone receptor (HR) positive patients had 25% and HER2 positive patients 12.5%. Median progression-free survival was 5.6 months (2.4-8.8 months, 95%CI) and longer in patients with triple negative breast cancer (TNBC) (median 7.4 months, 95%CI, 2.4-12.3 months) than the patients with other subtypes (median 5 months for HER2 positive and 3.6 months for HR positive patients). Median PFS of the patients with TNBC who received this regimen as first-line was 9.2 months (5.2-13.2 months, 95%CI). Conclusions: Cisplatin plus Gemcitabine may be a treatment option for patients with BM from breast cancer. Longer PFS and higher response rates are results that support the usage of this regimen especially for the triple negative subtype. However, further prospective and randomized trials are clearly required to provide more exact information.

#Breast cancer #brain metastases #cisplatin plus gemcitabine #triple negative

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

이 논문의 저자 정보

Erten, Cigdem

소속기관 Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital